Riva, N.; Brstilo, L.; Sancho-Araiz, A.; Molina, M.; Savransky, A.; Roffé, G.; Sanz, M.; Tenembaum, S.; Katsicas, M.M.; Trocóniz, I.F.;
et al. Population Pharmacodynamic Modelling of the CD19+ Suppression Effects of Rituximab in Paediatric Patients with Neurological and Autoimmune Diseases. Pharmaceutics 2023, 15, 2534.
https://doi.org/10.3390/pharmaceutics15112534
AMA Style
Riva N, Brstilo L, Sancho-Araiz A, Molina M, Savransky A, Roffé G, Sanz M, Tenembaum S, Katsicas MM, Trocóniz IF,
et al. Population Pharmacodynamic Modelling of the CD19+ Suppression Effects of Rituximab in Paediatric Patients with Neurological and Autoimmune Diseases. Pharmaceutics. 2023; 15(11):2534.
https://doi.org/10.3390/pharmaceutics15112534
Chicago/Turabian Style
Riva, Natalia, Lucas Brstilo, Aymara Sancho-Araiz, Manuel Molina, Andrea Savransky, Georgina Roffé, Marianela Sanz, Silvia Tenembaum, Maria M. Katsicas, Iñaki F. Trocóniz,
and et al. 2023. "Population Pharmacodynamic Modelling of the CD19+ Suppression Effects of Rituximab in Paediatric Patients with Neurological and Autoimmune Diseases" Pharmaceutics 15, no. 11: 2534.
https://doi.org/10.3390/pharmaceutics15112534
APA Style
Riva, N., Brstilo, L., Sancho-Araiz, A., Molina, M., Savransky, A., Roffé, G., Sanz, M., Tenembaum, S., Katsicas, M. M., Trocóniz, I. F., & Schaiquevich, P.
(2023). Population Pharmacodynamic Modelling of the CD19+ Suppression Effects of Rituximab in Paediatric Patients with Neurological and Autoimmune Diseases. Pharmaceutics, 15(11), 2534.
https://doi.org/10.3390/pharmaceutics15112534
